@article{fe41e34607ee43b383820d6ad52bc42d,
title = "miR147b: A novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes",
abstract = "Astrocytes are important mediators of inflammatory processes in the brain and seem to play an important role in several neurological disorders, including epilepsy. Recent studies show that astrocytes produce several microRNAs, which may function as crucial regulators of inflammatory pathways and could be used as therapeutic target. We aim to study which miRNAs are produced by astrocytes during IL-1β mediated inflammatory conditions in vitro, as well as their functional role and to validate these findings in human epileptogenic brain tissue. Sequencing was used to assess miRNA and mRNA expression in IL-1β-stimulated human fetal astrocyte cultures. miRNAs were overexpressed in cell cultures using miRNA mimics. Expression of miRNAs in resected brain tissue from patients with tuberous sclerosis complex or temporal lobe epilepsy with hippocampal sclerosis was examined using in situ hybridization. Two differentially expressed miRNAs were found: miR146a and miR147b, which were associated with increased expression of genes related to the immune/inflammatory response. As previously reported for miR146a, overexpression of miR147b reduced the expression of the pro-inflammatory mediators IL-6 and COX-2 after IL-1β stimulation in both astrocyte and tuberous sclerosis complex cell cultures. miR146a and miR147b overexpression decreased proliferation of astrocytes and promoted neuronal differentiation of human neural stem cells. Similarly to previous evidence for miR146a, miR147b was increased expressed in astrocytes in epileptogenic brain. Due to their anti-inflammatory effects, ability to restore aberrant astrocytic proliferation and promote neuronal differentiation, miR146a and miR147b deserve further investigation as potential therapeutic targets in neurological disorders associated with inflammation, such as epilepsy.",
keywords = "Astrocytes, inflammation, interleukin 1 beta, microRNA, temporal lobe epilepsy, tuberous sclerosis complex",
author = "{van Scheppingen}, Jackelien and Mills, {James D.} and Zimmer, {Till S.} and Broekaart, {Diede W.M.} and Valentina Iori and Anika Bongaarts and Anink, {Jasper J.} and Iyer, {Anand M.} and Anatoly Korotkov and Jansen, {Floor E.} and {van Hecke}, Wim and Spliet, {Wim G.} and {van Rijen}, {Peter C.} and Baayen, {Johannes C.} and Annamaria Vezzani and {van Vliet}, {Erwin A.} and Eleonora Aronica",
note = "Funding Information: European Union{\textquoteright}s Seventh Framework Programme (FP7/2007-2013), Grant Num ber: 602391 and 602102; the Dutch Epi lepsy Foundation, Grant Number: 13-01 and 16-05; European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme, Marie Sklodowska-Curie, Grant Number: 642881 and 722053 Funding Information: The research leading to these results has received funding from the European Union{\textquoteright}s Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 602391 (EPISTOP; J. v. S., E. A., F. E. J.) and no. 602102 (EPITARGET; E. A., E. A. v. V., A. V.), the Dutch Epilepsy Foundation, project number 13-01 (E. A., V. I., A. V.) and 16-05 (D. W. M. B., E. A. v. V.) and the European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement no. 642881 (ECMED; A. K., E. A.) and no. 722053 (EU-GliaPhD; T. S. Z., E. A.). We acknowledge the HIS Mouse Facility of the Academic Medical Center, Amsterdam and the Bloemenhove Clinic (Heemstede, The Netherlands) for providing fetal tissues. Funding Information: The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007?2013) under grant agreement no. 602391 (EPISTOP; J. v. S., E. A., F. E. J.) and no. 602102 (EPITARGET; E. A., E. A. v. V., A. V.), the Dutch Epilepsy Foundation, project number 13-01 (E. A., V. I., A. V.) and 16-05 (D. W. M. B., E. A. v. V.) and the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement no. 642881 (ECMED; A. K., E. A.) and no. 722053 (EU-GliaPhD; T. S. Z., E. A.). We acknowledge the HIS Mouse Facility of the Academic Medical Center, Amsterdam and the Bloemenhove Clinic (Heemstede, The Netherlands) for providing fetal tissues. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = may,
day = "1",
doi = "10.1002/glia.23302",
language = "English",
volume = "66",
pages = "1082--1097",
journal = "GLIA",
issn = "0894-1491",
publisher = "John Wiley & Sons Inc.",
number = "5",
}